[Morphazinamide in antitubercular therapy. 2 years of clinical experimentation].
D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use
D000995:Antitubercular Agents; D011719:Pyrazines
La morfazinamide nella terapia antitubercolare. Due anni di sperimentazione clinica.